Therapeutic and diagnostic methods for cancer

US11674962B2 · kind B2 · utility

Assignees

• Genentech, Inc. · US
• Foundation Medicine, Inc. · US

Inventors

• Craig Cummings · Pacifica, US
• Yan Li · Tallahassee, US
• Sarah Margaret SHAGAN · South San Francisco, US
• Erica Beth SCHLEIFMAN · South San Francisco, US
• David Shames · South San Francisco, US
• David Fabrizio · Hamilton, US
• Daniel LIEBER · Cambridge, US
• Geoffrey Otto · Brookline, US
• Mark KENNEDY · Cambridge, US
• Travis CLARK · Woodway, US
• Doron Lipson · Cambridge, US
• Jie He · Newton, US
• Shan ZHONG · Belmont, US

Key dates

• Filing date: Jul 20, 2018
• Grant date: Jun 13, 2023
• Expiry date: Jan 30, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A90/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.